Advertisement
Canada markets close in 5 hours 39 minutes

  • S&P/TSX

    22,001.55
    +129.59 (+0.59%)
     

  • S&P 500

    5,055.51
    +44.91 (+0.90%)
     

  • DOW

    38,410.97
    +170.99 (+0.45%)
     

  • CAD/USD

    0.7321
    +0.0020 (+0.27%)
     

  • CRUDE OIL

    82.05
    +0.15 (+0.18%)
     

  • Bitcoin CAD

    91,426.25
    +874.98 (+0.97%)
     

  • CMC Crypto 200

    1,430.92
    +16.16 (+1.14%)
     

  • GOLD FUTURES

    2,343.10
    -3.30 (-0.14%)
     

  • RUSSELL 2000

    1,994.74
    +27.27 (+1.39%)
     

  • 10-Yr Bond

    4.5840
    -0.0390 (-0.84%)
     

  • NASDAQ

    15,638.00
    +186.70 (+1.21%)
     

  • VOLATILITY

    16.36
    -0.58 (-3.42%)
     

  • FTSE

    8,036.39
    +12.52 (+0.16%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6836
    -0.0014 (-0.20%)
     
MARKETS LIVE BLOG:

STOCKS EXTEND GAINS AS RESULTS SEASON KICKS INTO HIGH GEAR

Tech-focused investors prepare for fresh wave of earnings highlighted by struggling Tesla

Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

Cara Therapeutics, Inc.
·1 min read
Cara Therapeutics, Inc.
Cara Therapeutics, Inc.

STAMFORD, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, March 6, 2023, at 4:30 p.m. EST to report fourth quarter and full year 2022 financial results and provide a corporate update.

To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN.

A live audio webcast and archived replay of the call will be available under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.

ADVERTISEMENT

About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica and plans to initiate a Phase 2/3 clinical trial program in the first quarter of 2023. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com